The new cancer fighting drug, Opdivo, could be the next miracle drug of the future. Shares of Bristol-Myers Squibb could also perform miraculously for long term investors.
Opdivo has shown tremendous success in stopping the progression of numerous types of cancer including cancers of the head and neck, lung cancer, renal cell cancer, as well as the deadly skin cancer melanoma. This drug is the front runner when speaking of the new immuno-oncology drugs, which are prolonging the lives of persons affected with late stage cancers. Although this drug is not completely free from side effects, it has considerably fewer noted side effects than current cancer treatments, such as chemotherapy.
Opdivo blocks important receptors in T-cells, which improves the patients own immune system, allowing it to recognize and attack mutant cancer cells and cancerous tumors. To date, Opdivo has been the most successful in this new class of cancer drugs, even outperforming some of Bristol-Myers (Ticker: BMY) other drugs, such as Yervoy, in this same class. In fact, at least 5 clinical trials have been stopped early because it was obvious that Odivo was greatly increasing survival rates by slowing or stopping the advancement of cancer. The Food and Drug Administration has given no fewer than 7 approvals for Opdivo to treat certain types of cancer in 2015.
After Bristol-Myers stock rose during the summer of 2015 from $60 to $70.87, it took a nose dive in the fall that found it back at $60 by December. Even at $60, this isn’t considered to be a cheap stock, but for investors who are interested in the long haul, this is one they should seriously consider buying.
If Opdivo isn’t enough to sway some people to invest in this stock, perhaps they should reconsider. The company has other promising cancer treatments coming down the proverbial pipeline. Some market analysts see the stock by 25% or more next year. One company, Cowen & Company, states that they even forsee this stock hitting the $100 mark by the end of the year.
Bristol-Myer also had staggering fourth quarter results last year with revenue of $4.3 billion and earnings of 38 cents per share, which was well above expectations.
Although the stock isn’t necessarily a bargain right now, especially when compared to stocks like Merck, but Bristol-Myers drug Opdivo is certainly kicking Mercks behind right now by outperforming Mercks drug Keytruda.
It’s all about Opdivo right now and that is what will be the driving force behind this drugmakers stock, at least for 2016. A T.Rowe Price manager stated that this is one of the best pharmaceutical stocks to come along in quite some time and that long term investors should ride this stock all the way to the bank.
Source: Barron’s
xThe new cancer fighting drug, Opdivo, could be the next miracle drug of the future. Shares of Bristol-Myers Squibb could also perform miraculously for long term investors.
Opdivo has shown tremendous success in stopping the progression of numerous types of cancer including cancers of the head and neck, lung cancer, renal cell cancer, as well as the deadly skin cancer melanoma. This drug is the front runner when speaking of the new immuno-oncology drugs, which are prolonging the lives of persons affected with late stage cancers. Although this drug is not completely free from side effects, it has considerably fewer noted side effects than current cancer treatments, such as chemotherapy.
Opdivo blocks important receptors in T-cells, which improves the patients own immune system, allowing it to recognize and attack mutant cancer cells and cancerous tumors. To date, Opdivo has been the most successful in this new class of cancer drugs, even outperforming some of Bristol-Myers (Ticker: BMY) other drugs, such as Yervoy, in this same class. In fact, at least 5 clinical trials have been stopped early because it was obvious that Odivo was greatly increasing survival rates by slowing or stopping the advancement of cancer. The Food and Drug Administration has given no fewer than 7 approvals for Opdivo to treat certain types of cancer in 2015.
History
After Bristol-Myers stock rose during the summer of 2015 from $60 to $70.87, it took a nose dive in the fall that found it back at $60 by December. Even at $60, this isn’t considered to be a cheap stock, but for investors who are interested in the long haul, this is one they should seriously consider buying.
If Opdivo isn’t enough to sway some people to invest in this stock, perhaps they should reconsider. The company has other promising cancer treatments coming down the proverbial pipeline. Some market analysts see the stock by 25% or more next year. One company, Cowen & Company, states that they even forsee this stock hitting the $100 mark by the end of the year.
Bristol-Myer also had staggering fourth quarter results last year with revenue of $4.3 billion and earnings of 38 cents per share, which was well above expectations.
Although the stock isn’t necessarily a bargain right now, especially when compared to stocks like Merck, but Bristol-Myers drug Opdivo is certainly kicking Mercks behind right now by outperforming Mercks drug Keytruda.
It’s all about Opdivo right now and that is what will be the driving force behind this drugmakers stock, at least for 2016. A T.Rowe Price manager stated that this is one of the best pharmaceutical stocks to come along in quite some time and that long term investors should ride this stock all the way to the bank.
Source: Barron’s
Leave a Reply